Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
| 63.89 | |
| 63.89 | |
| - | |
| 63.89 | |
| 63.89 | |
| 38.36-69.35 | |
| 11 990 M | |
| 185 M | |
| 2 612 M | |
| 1.273 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the f...
Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal c...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
